Abstract:You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Penis/Testis/Urethra: Malignant Disease1 Apr 2015MP10-11 PELVIC EXTRANODAL EXTENSION LEADS TO WORSE OUTCOMES IN PENILE CANCER PATIENTS WITH POSITIVE PELVIC LYMPH NODES AND IS ASSOCIATED WITH A SURVIVAL BENEFIT AFTER ADJUVANT CHEMOTHERAPY: A MULTI-INSTITUTIONAL STUDY Pranav Sharma, Rosa Djajadiningrat, Kamran Zargar-Shoshtari, Mario Catanzaro, Yao Zhu, Nicola Nicolai, Simon Horenblas, and Philippe Spiess Pranav SharmaPranav Sharma More articles by this author , Rosa DjajadiningratRosa Djajadiningrat More articles by this author , Kamran Zargar-ShoshtariKamran Zargar-Shoshtari More articles by this author , Mario CatanzaroMario Catanzaro More articles by this author , Yao ZhuYao Zhu More articles by this author , Nicola NicolaiNicola Nicolai More articles by this author , Simon HorenblasSimon Horenblas More articles by this author , and Philippe SpiessPhilippe Spiess More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.412AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although penile cancer patients with positive pelvic lymph nodes (PPLN) have a poor prognosis, the natural history, recurrence patterns, risk factors of survival, and impact of adjuvant therapy are not well understood. Using multi-institutional data across four tertiary referral centers, we aimed to clarify the answers to these questions. METHODS We identified 141 patients from 1978 to 2014 with PPLN after pelvic lymph node dissection (PLND) for metastatic squamous cell carcinoma (SCC) of the penis. Relevant clinical and pathological characteristics were identified and recorded via retrospective chart review, and vital status was noted from the time of PLND until last follow-up or date of death. Multivariate Cox regression was performed to evaluate the association of these variables with overall survival (OS), which was estimated using the Kaplan-Meier method. Differences in OS between relevant subgroups was determined with the log-rank test. RESULTS Median number of positive inguinal LN in our patient population was 4 (interquartile range [IQR]: 2 – 5) with 58.9% of cases occurring bilaterally in the groin and 78.7% having inguinal extranodal extension (ENE). Median number of PPLN was 2 (IQR: 1 – 4) with 55.8% of cases having pelvic ENE. Neoadjuvant chemotherapy was used in 27.0% of patients, adjuvant radiation therapy (XRT) in 39.0%, adjuvant chemotherapy in 27.7%, and salvage chemotherapy in 13.5%. Disease progression was seen in 12.8% of patients while disease recurrence was seen in 58.2% of patients. Of those recurrences, 48.8% occurred distantly, 46.3% occurred regionally in the groin or pelvis, and 4.9% occurred locally in the penile bed. Median OS in our patient population was 13.3 months (IQR: 6.9 – 33.1). ENE in the pelvic LNs was independently associated with worse OS (hazard ratio [HR]: 1.622; 95% confidence interval [CI]: 1.029-2.557; p=0.037) with a median OS of 11.1 months (IQR: 5.2 – 26.6) vs 15.4 (IQR: 9.2 – 104) in patients without pelvic ENE. Use of adjuvant chemotherapy improved OS in pelvic ENE positive patients (20.7 vs 8.0 months; p=0.001) but was not as effective in pelvic ENE negative patients (21.7 vs 14.4 months; p=0.207). CONCLUSIONS Penile cancer patients with PPLN have a significant mortality risk and a high distant recurrence rate. Pelvic ENE is a poor prognostic factor that impacts survival, but use of adjuvant chemotherapy can be associated with improved outcomes. Prospective studies are needed to further investigate these findings. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e115 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pranav Sharma More articles by this author Rosa Djajadiningrat More articles by this author Kamran Zargar-Shoshtari More articles by this author Mario Catanzaro More articles by this author Yao Zhu More articles by this author Nicola Nicolai More articles by this author Simon Horenblas More articles by this author Philippe Spiess More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Extent of Pelvic Lymph Node Dissection in Penile Cancer May Impact Survival

Pelvic Lymph Node Dissection in Penile Cancer with Inguinal Lymph Node Extranodal Extension: A Multicenter Experience.

Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

MP10-11 PELVIC EXTRANODAL EXTENSION LEADS TO WORSE OUTCOMES IN PENILE CANCER PATIENTS WITH POSITIVE PELVIC LYMPH NODES AND IS ASSOCIATED WITH A SURVIVAL BENEFIT AFTER ADJUVANT CHEMOTHERAPY: A MULTI-INSTITUTIONAL STUDY

Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database

The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Risk Prostate Cancer: A Population-Based Study

Identifying the Candidates Who Will Benefit from Extended Pelvic Lymph Node Dissection at Radical Prostatectomy among Patients with Prostate Cancer.

Adjuvant Pelvic Radiation is Associated with Improved Survival and Decreased Disease Recurrence in Pelvic Node-Positive Penile Cancer after Lymph Node Dissection: A Multi-Institutional Study

Management of Lymph Node-positive Penile Cancer: A Systematic Review

Prognostic Value of Bilateral Inguinal Lymph Node Metastases in Node-Positive Penile Cancer

Oncological and Survival Outcomes of Pelvic Lymph Node Dissection in Patients with Nonmuscle Invasive Bladder Cancer Undergoing Radical Cystectomy Using the National Cancer Database

Deep Inguinal Lymph Node Metastases Can Predict Pelvic Lymph Node Metastases and Prognosis in Penile Squamous Cell Carcinoma.

Lymph Node Dissections for T3T4 Stage Penile Cancer Patients Without Preoperatively Detectable Lymph Node Metastasis Bring More Survival Benefits: A Propensity Matching Analysis

Contemporary Use Trends and Effect on Survival of Pelvic Lymph Node Dissection for Non-Muscle-invasive Bladder Cancer.

Lymph Node Mapping in Patients with Penile Cancer Undergoing Pelvic Lymph Node Dissection (Publication with Expression of Concern)

Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy

A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma

Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association

Identifying an optimal lymph node yield for penile squamous cell carcinoma: Prognostic impact of surgical dissection.

Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference?